John Aslanian, Aesthetic Medicine Practitioner | Former Graphic Arts Executive & Contributor to PDF Standards – Precision Aesthetics
The global aesthetics market has quietly grown from a niche corner of medicine into a mainstream, multibillion-dollar industry. When surgical and non-surgical aesthetics are combined, current estimates range from roughly $30 billion to north of $90 billion, with some analysts projecting $150–$200 billion by the mid-2030s.
Surgical procedures—facelifts, liposuction, body contouring—remain high-ticket but are limited by recovery time, risk, and patient tolerance. Non-surgical aesthetics, by contrast, is where the real growth has occurred: repeatable treatments, lower risk, and far broader consumer adoption.
I’ve spent the past two decades in New York—arguably the richest and most competitive aesthetics market in the world—focused exclusively on the non-surgical side. We were likely among the first practices to go 100% non-surgical, recognizing early that many patients wanted results without surgery, rather than being a plastic surgery practice that simply added Botox and fillers.
Today, forecasts suggest the non-surgical market alone could more than double—from roughly $19.5 billion in 2025 to over $40 billion by 2031, with global estimates for injectables and energy-based devices exceeding $80 billion.
2001: The Beginning — Just Botox and Fillers
Twenty years ago, non-surgical aesthetics was simple. There were essentially two tools: Botox and dermal fillers.
They offered predictable, short-term results, but there was no real technology behind rejuvenation—no way to address the structural aging of skin, only temporary fixes for wrinkles or volume loss.
That changed with the first meaningful device breakthrough.
Thermage: Collagen Without Burning the Skin
In 2001, the first true aesthetic “device” entered the market. Radiofrequency (RF) energy was introduced as a way to heat deeper layers of skin without damaging the surface. For the layperson, the analogy is simple: it’s the frustration of trying to brown chicken skin in a microwave. Thermage figured out how to harness that energy and direct it precisely to the collagen layer, tightening skin and stimulating collagen production without burning the surface—and patented the approach.
Our medical director, Dr. Lisa A. Zdinak, along with Danielle Braz, was directly involved in testing and validating the technology. At the time, we shared space with one of New York’s most respected plastic surgeons. His verdict was blunt: “It’s a toy.”
Within a few years, that same surgeon was asking us to tighten and build collagen before performing facelifts.
2009: Exilis and the Next Wave
Another inflection point came in 2009 with the introduction of Exilis by BTL. Dr. Zdinak was lecturing on Thermage at the Monte Carlo Anti-Aging Congress, presenting one of its most meaningful upgrades.
At that conference, after meeting BTL’s president—now best known for Emsculpt—we were tasked with bringing the first Exilis system to the United States. It combined radiofrequency and ultrasound to address both skin tightening and fat, reinforcing the idea that multi-layer treatment would define the future of non-surgical aesthetics.
The CoolSculpting Phenomenon—and Its Problems
In 2016, the industry experienced one of its biggest marketing explosions with fat-freezing technology, most notably CoolSculpting. The concept was elegant: kill fat cells by freezing them. The company backed that idea with an estimated $100 million marketing budget in a single year, rivaling legacy consumer brands.
Suddenly, even my male friends in Tennessee—far outside the traditional aesthetics demographic—were seeing billboards and knew the term. Clinically, however, the reality was far more complicated.
When fat cells are destroyed via freezing, the body doesn’t automatically retract surrounding tissue. The result can be loose skin and a deflated appearance. Worse, a rare but real complication—paradoxical adipose hyperplasia—occurs in roughly 1 in 100 patients, causing fat to grow back harder, denser, and larger, often requiring surgical removal.
Despite the millions in revenue it generated for those who offered it, it was a hard pass for us. Public perception shifted after a high-profile case involving Linda Evangelista, reinforcing a lesson this industry repeatedly learns: marketing momentum can outrun clinical reality.
2018: Muscle Stimulation Goes Mainstream
In 2018, another category exploded with the introduction of Emsculpt, a muscle-stimulation platform. Fueled by social media, professional athletes, fitness influencers, and pop stars openly showcased six-pack abs achieved without traditional workouts.
For the first time, non-surgical aesthetics wasn’t just about appearance—it was about strength and function, including measurable benefits like core engagement and back support. Treatment volumes and social media impressions were staggering, pulling an entirely new audience into the industry.
2020–2025: Microneedling Meets RF—and Its Dark Side
Around 2020, another surge followed with devices combining radiofrequency and microneedling. Adoption accelerated rapidly and peaked around 2025. But delivering RF energy below the skin’s surface—particularly in unskilled hands—introduced real risks, including scarring and tissue damage, prompting recent FDA warnings.
The Core Tech Stack
Despite the constant stream of “revolutionary” devices, the underlying technology hasn’t fundamentally changed. It still comes down to a few energy categories under different brand names:
• Radiofrequency for deep tissue heating and skin tightening
• Muscle stimulation using electromagnetic energy
• Acoustic wave therapy, adapted from physical therapy, effective for cellulite
• Ultrasound, useful on the body but riskier near facial nerves
• Lasers, primarily superficial
Most new platforms are variations on these themes, marketed as breakthroughs despite incremental differences.
Business Realities: Bottles, Bills, and the One-Off Model
Injectables operate on tight margins. At $300–$600 per unit, providers must choose between being generous and eroding profit, or conservative and risking unhappy patients.
Unlike traditional B2B businesses, aesthetics has no contracts. Every day starts at zero. Patients are in and out within an hour, and if no one walks in tomorrow, revenue stops tomorrow.
Even surgery doesn’t solve this. Facelifts costing $30,000 to $250,000 don’t stop aging. Collagen and muscle decline roughly 2% per year after age 40, meaning even the most expensive surgery fades with time.
Manufacturers as the Hidden Competitors
One of the biggest challenges in aesthetics isn’t other practices—it’s the manufacturers.
Devices costing hundreds of thousands of dollars are quickly followed by “upgrades” promising marginal gains. Direct-to-consumer marketing trains patients to demand the latest version, forcing providers onto a technology treadmill.
Many devices now include planned obsolescence—limited pulse counts, mandatory service contracts, or pay-to-play models that create a permanent cost per treatment for the practice.
The Bottom Line
Aesthetics sits at the intersection of medicine, consumer desire, and marketing hype. Clinical innovation has been incremental, not revolutionary, despite what advertising suggests. Friends regularly send me the “next big thing.” It’s almost always a variation on energy sources discovered years ago.
The winners in this business aren’t defined by who owns the newest machine, but by judgment, restraint, experience, and business fundamentals.
Old truths still apply. If a tree falls in the forest and no one sees it, it doesn’t matter how advanced the technology is. With devices capable of generating $1,000–$4,000 an hour, many assume aesthetics is an easy entry. It isn’t. Unlike B2B, you can’t put people under contract.
The real challenge—now more than ever—is building a predictable, sustainable stream of clients. And no machine can do that for you.
Author Bio
John has spent two decades running a non-surgical aesthetics practice in New York City. He also ran a notable graphic arts company retouching iconic brands and women—digitally doing what his current company now does physically—and contributed to developing and validating early PDF standards.
New York, NY 10023